Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Ole A. Mandrup
  • Sui Ching Ong, Aarhus University
  • ,
  • Simon Lykkemark
  • ,
  • Anders Dinesen
  • Imke Rudnik-Jansen
  • Niels Frederik Dagnæs-Hansen
  • ,
  • Jan Terje Andersen, University of Oslo, Institute of Clinical Medicine and Department of Pharmacology
  • ,
  • Luis Alvarez-Vallina, Cancer Immunotherapy Unit (UNICA), Immuno-Oncology and Immunotherapy Group, University of Valencia
  • ,
  • Kenneth A. Howard

Fc-less bispecific T-cell engagers have reached the immuno-oncology market but necessitate continual infusion due to rapid clearance from the circulation. This work introduces a programmable serum half-life extension platform based on fusion of human albumin sequences engineered with either null (NB), wild type (WT) or high binding (HB) FcRn affinity combined with a bispecific T-cell engager. We demonstrate in a humanised FcRn/albumin double transgenic mouse model (AlbuMus) the ability to tune half-life based on the albumin sequence fused with a BiTE-like bispecific (anti-EGFR nanobody x anti-CD3 scFv) light T-cell engager (LiTE) construct [(t½ 0.6 h (Fc-less LiTE), t½ 19 hours (Albu-LiTE-NB), t½ 26 hours (Albu-LiTE-WT), t½ 37 hours (Albu-LiTE-HB)]. We show in vitro cognate target engagement, T-cell activation and discrimination in cellular cytotoxicity dependent on EGFR expression levels. Furthermore, greater growth inhibition of EGFR-positive BRAF mutated tumours was measured following a single dose of Albu-LiTE-HB construct compared to the Fc-less LiTE format and a full-length anti-EGFR monoclonal antibody in a new AlbuMus RAG1 knockout model introduced in this work. Programmable half-life extension facilitated by this albumin platform potentially offers long-lasting effects, better patient compliance and a method to tailor pharmacokinetics to maximise therapeutic efficacy and safety of immuno-oncology targeted biologics.

Original languageEnglish
JournalCommunications Biology
Volume4
Issue1
Pages (from-to)310
Number of pages1
DOIs
Publication statusPublished - 8 Mar 2021

Bibliographical note

Copyright:
This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine

See relations at Aarhus University Citationformats

ID: 215391824